Company Performance Metrics
- Johan Frostegard: Co-Founder
- Susanne Andersson: Chief Financial Officer
Annexin Pharmaceuticals AB (publ) is a world-leading biotechnology company within the Annexin A5 area, for the treatment of various cardiovascular diseases.
The company's biological drug candidate ANXV - a human recombinant protein, Annexin A5 - is primarily intended for acute treatment of patients with cardiovascular diseases with injuries
and inflammation in the blood vessels. In addition, the company has an extensive patent portfolio for the treatment of diseases that arise due to damage and inflammation of the blood vessels. Annexin Pharmaceuticals has established and optimized a cell line for large-scale manufacturing of Annexin A5. The production process is patent-pending.
ANXV has the ability to protect and repair the blood vessels and to counteract the inflammation. Thus, ANXV is expected to reduce suffering and hopefully mortality for several patient groups with both rare vascular diseases and major diseases such as heart attack.
ANXV has the potential to become First-In-Class (product with new unique mechanisms of action that is the first of its kind in the market) for several patient groups where there are large unmet medical treatment needs.
